» Articles » PMID: 37043728

Management of Patients With Pancreatic Cancer Using the "Right Track" Model

Overview
Journal Oncologist
Specialty Oncology
Date 2023 Apr 12
PMID 37043728
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic cancer is one of the few cancer types in the US with incidence and death rates continuing to rise. As the disease threatens to become the second leading cause of cancer-related deaths in the country, it is imperative to review the best practices currently available to extend and improve patient lives. To provide a roadmap for healthcare professionals detecting, diagnosing, and caring for patients with pancreatic cancer as a supplement to national guidelines focused on recommended treatment regimens, the Pancreatic Cancer Action Network (PanCAN)'s Scientific and Medical Affairs staff and expert Scientific and Medical Advisory Board have created a series of position statements. The statements are based upon scientific evidence and clinical observations published in the literature and research conducted through PanCAN's internal programs and initiatives. This review summarizes the rationale and sources for these position statements related to diagnosis, treatment, and care for pancreatic cancer and provides information about resources to make these recommendations accessible to patients and their medical teams. Pancreatic cancer is a complex and extremely challenging disease. Beyond treatment recommendations outlined in national guidelines, steps can be taken to help patients feel better and live longer. Under the framework of the "Right Track" model-right team, right tests, right treatments, data sharing-PanCAN's position statements can provide supplementary guidance to healthcare professionals for the short- and long-term management of patients with the disease.

Citing Articles

Cancer mutationscape: revealing the link between modular restructuring and intervention efficacy among mutations.

Plaugher D, Murrugarra D NPJ Syst Biol Appl. 2024; 10(1):74.

PMID: 39003264 PMC: 11246485. DOI: 10.1038/s41540-024-00398-6.


Associations between Diabetes Mellitus and Selected Cancers.

Pliszka M, Szablewski L Int J Mol Sci. 2024; 25(13).

PMID: 39000583 PMC: 11242587. DOI: 10.3390/ijms25137476.


Dysbiosis Signature of Fecal Microbiota in Patients with Pancreatic Adenocarcinoma and Pancreatic Intraductal Papillary Mucinous Neoplasms.

Sidiropoulos T, Dovrolis N, Katifelis H, Michalopoulos N, Kokoropoulos P, Arkadopoulos N Biomedicines. 2024; 12(5).

PMID: 38791002 PMC: 11117863. DOI: 10.3390/biomedicines12051040.


Pancreatic cancer mutationscape: revealing the link between modular restructuring and intervention efficacy amidst common mutations.

Plaugher D, Murrugarra D bioRxiv. 2024; .

PMID: 38352601 PMC: 10862704. DOI: 10.1101/2024.01.27.577546.


FROM LEFT TO RIGHT. PARA-AORTIC LYMPH NODES SAMPLING DURING PANCREATODUODENECTOMY FOR PANCREATIC CANCER.

Stevenin G, Guyard C, Lupinacci R Arq Bras Cir Dig. 2023; 36:e1772.

PMID: 37971025 PMC: 10642947. DOI: 10.1590/0102-672020230054e1772.


References
1.
Bilimoria K, Bentrem D, Ko C, Stewart A, Winchester D, Talamonti M . National failure to operate on early stage pancreatic cancer. Ann Surg. 2007; 246(2):173-80. PMC: 1933550. DOI: 10.1097/SLA.0b013e3180691579. View

2.
Kotecha R, Sahgal A, Mehta M . Adagrasib in Non-Small-Cell Lung Cancer. N Engl J Med. 2022; 387(13):1238-1239. DOI: 10.1056/NEJMc2210539. View

3.
van Rijssen L, Gerritsen A, Henselmans I, Sprangers M, Jacobs M, Bassi C . Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC): An International Delphi Study Among Patients and Health Care Providers. Ann Surg. 2017; 270(1):158-164. DOI: 10.1097/SLA.0000000000002633. View

4.
Basch E, Deal A, Kris M, Scher H, Hudis C, Sabbatini P . Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol. 2015; 34(6):557-65. PMC: 4872028. DOI: 10.1200/JCO.2015.63.0830. View

5.
Kemp S, Cheng N, Markosyan N, Sor R, Kim I, Hallin J . Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer. Cancer Discov. 2022; 13(2):298-311. PMC: 9900321. DOI: 10.1158/2159-8290.CD-22-1066. View